A recent report published by
Infinium Global Research on the migraine drugs market provides an in-depth analysis of
segments and sub-segments in the global as well as regional migraine drugs
market. The study also highlights the impact of drivers, restraints, and macro
indicators on the global and regional migraine drugs market over the short term
as well as long term. The report is a comprehensive presentation of trends,
forecasts, and dollar values of global migraine drugs market. According to the
report, the global migraine drugs market is projected to grow at a CAGR of
8.38% over the forecast period of 2020-2026.
Market Insight
Migraine is a clinical condition
of neurology which can cause numerous symptoms. It is marked often by
severe and devastating headaches. Symptoms can consist of nausea, vomiting,
difficulty speaking, numbness or tingling, and several others. Furthermore, the
diagnosis of migraine headaches is evaluated from clinical history and reported
symptoms. Moreover, females are more prone to experience migraines than men.
Genetic background is one of the most general sign factors for migraines.
Symptoms of migraines will start one to two days before the headache itself and
this is categorized as a stage of the prodrome. In addition, migraine pain
frequently impacts the area of the forehead. It's usually on one side of the
head, but on both sides, it may arise. Migraines are more common in women, with
17.0% of women reporting an attack compared to 6.0% men, each year. The global
Migraine Drugs market was sized near USD 4.80 billion in 2019. The Migraine
Drugs market is expected to grow at a CAGR of 8.38% during the forecast period.
The growing awareness regarding
migraine and numerous options available for its treatment are the major factors
responsible for the growth of the global migraine drugs market in the near
future. A number of organizations comprising the American Headache and Migraine
Association are taking efforts to spread awareness about migraine and therefore
coming up with programs and offering support to patients so as to spread
awareness regarding the disease and further disorders associated with a
headache. However, Migraine preventive medicines such as beta-blockers, calcium
channel blockers, and antidepressants are also associated with adverse side
effects such as fatigue, depression, dizziness, lowered blood pressure, weight
gain, constipation, sedation, decreased libido among others. Many patients are
unable to tolerate these side effects and discontinue their treatments. This
has led to a decline in the acceptability of drugs used for the treatment of
migraines. Moreover, owing to the growing number of migraine incidences and an
increasing number of unmet needs in the global migraine drugs market, a number
of vendors are planning to invest in the migraine drugs R&D. This, in turn,
is estimated to propel the global migraine drugs market growth over the
projection period.
Among the regions, North America
dominates the global migraine drugs market followed by Europe. Migraine is the
third most prevalent and the sixth most disabling illness across the globe,
affecting more than 37 million in the United States and over one billion people
worldwide. The increasing prevalence of migraines and the increasing adoption
of novel therapeutics are the major demand driving factors in the North
American region. Furthermore, in the European region, the increasing geriatric
population and better reimbursement policies are upsurging the demand for
migraine drugs. However, the Asia Pacific region is expected to grow at a rapid
rate over the forecast period owing to the presence of emerging opportunities,
improving healthcare infrastructure, and increasing patient awareness. In
addition, the low-cost production of drugs across the region is one of the
significant growth drivers for this market.
Segment Covered
The report on the global migraine
drugs market covers segments such as therapeutic class, and treatment type. On
the basis of therapeutic class, the sub-markets include ergot, triptans, and
others. On the basis of treatment type, the sub-markets include abortive, and abortive
preventive.

Companies Profiled:
The report provides profiles of
the companies in the market such as GlaxoSmithKline PLC, Amgen Inc., ALLERGAN
PLC, ELI LILY & Company, Merck KGaA, Amneal Pharmaceuticals Inc., H.
Lundbeck A/S, Neurelis Inc., Pfizer Inc., and Zogenix, Inc..
Report Highlights:
The report provides deep insights
into the demand forecasts, market trends, and micro and macro indicators. In
addition, this report provides insights into the factors that are driving and
restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis
given in the report brings an insight into the investment areas that existing
or new market players can consider. The report provides insights into the
market using analytical tools such as Porter's five forces analysis and DRO
analysis of migraine drugs market. Moreover, the study highlights current
market trends and provides forecast from 2020-2026. We also have highlighted
future trends in the market that will affect the demand during the forecast
period. Moreover, the competitive analysis given in each regional market brings
an insight into the market share of the leading players.